ArticleCureus2025
A Study to Improve the Safety of Transplantation: Is Control Necessary for Detecting Human Adenovirus in Umbilical Cord Blood Units?
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUmbilical cord blood (UCB) units are an alternative valuable source for allogeneic hematopoietic stem cells (allo-HSCT). Patients undergoing allo-HSCT remain at high risk for complications and mortality due to viral infections such as human adenovirus (HAdV). HAdV, a double-stranded DNA virus, has been detected in the full-term placenta, raising concerns about vertical transmission. This study aims to examine the presence of HAdV in UCB samples to improve the safety of transplantation procedures. Methods: A total of 98 UCB plasma samples were assayed to detect the presence of HAdV DNA using real-time polymerase chain reaction (PCR) technology Results: Of the 98 UCB plasma samples analyzed for HAdV, three tested positive (3.06%). In control testing for prevalent pathogens, 67.3% of the samples were Cytomegalovirus (CMV) IgG-positive (indicating past infection) and 4.2% were CMV IgM-positive (recent or active infection). All the samples were negative for human T-lymphotropic virus I-II (HTLV_I-II), hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), and human immunodeficiency virus I-II (HIV_I-II).
conclusionsThe detection of HAdV in a subset of UCB samples highlights the need to consider molecular screening for HAdV as part of routine safety evaluations in allogeneic UCB transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.